1.
An. bras. dermatol
;
91(5): 642-644, Sept.-Oct. 2016. graf
Artículo
en Inglés
| LILACS
| ID: biblio-827761
RESUMEN
Abstract: Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refractory Sézary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response. The treatment was discontinued after 4 months due to adverse effects, with the patient showing a sustained response without disease progression after 13 months of follow-up.
Asunto(s)
Humanos , Masculino , Anciano , Neoplasias Cutáneas/tratamiento farmacológico , Síndrome de Sézary/tratamiento farmacológico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Antineoplásicos/uso terapéutico , Neoplasias Cutáneas/sangre , Recuento de Células Sanguíneas , Antígenos de Diferenciación de Linfocitos T/metabolismo , Síndrome de Sézary/sangre , Resultado del Tratamiento , Alemtuzumab
2.
Arch. argent. dermatol
;
44(4): 187-8, jul.-ago. 1994. ilus
Artículo
en Español
| LILACS
| ID: lil-141620